Departments
of *Anesthesiology and tBiostatistics, University of Michigan Medical School, Ann Arbor, Michigan Ketorolac tromethamine (Toradol@) is a parenteral, nonsteroidal antiinflammatory drug that is being extensively used to provide postoperative analgesia. This study evaluated whether intraoperative ketorolac would act synergistically with fentanyl to decrease postoperative analgesic requirements in outpatients undergoing gynecologic procedures. The patients studied were adult ASA physical status I or II females scheduled for diagnostic laparoscopy (DL) (n = 80) or laparoscopic tubal ligation (TL) (n = 46). Each patient received fentany12 pg/kg intravenously (IV) before induction, followed by a standardized propofol anesthetic and 2 mL of saline or ketorolac 60 mg IV in a randomized double-blind fashion 30 min before the anticipated end of the operative procedure. Patients were assessed for postoperative pain via a lo-cm visual analog scale WAS) (0 = no pain; 10 = severe pain) before analgesic treatment in the postanesthesia care unit (PACU).
Severe postoperative pain (VAS of 5 or more) was treated with incremental doses of fentanyl, 25-50 pg IV by a blinded PACU nurse. Ibuprofen or acetaminophen with codeine was administered for pain control once the patient tolerated oral medications. This study showed that intraoperative ketorolac (60 mg IV) with fentanyl(2 pg/kg IV) administered at the induction of anesthesia resulted in significant opioid sparing and a diminution in pain in the DL sample but not in the TL sample. The analgesic regimen was also associated with a lower incidence of nausea and vomiting and resulted in earlier discharge, which was not seen after TL. These results demonstrate that pain after TL is far greater than that after DL, which suggests that these procedures should be considered separately when designing analgesic regimens.
(Anesth Analg 1996;82:732-7) P o&operative pain and the side effects traditionally associated with opioids continue to be a major problem in outpatient anesthesia (1,2). Providing adequate postoperative analgesia in women after outpatient laparoscopy while meeting the criteria for discharge within a reasonable time continues to be a challenge. Ketorolac (Toradol@; Syntex, Palo Alto, CA) is a parental, nonsteroidal antiinflammatory analgesic (NSAID) that has analgesic properties comparable to morphine (3-5). Ketorolac also alleviates moderate to severe pain in the postoperative period while diminishing the incidence of side effects typically associated with opioids (6). Ketorolac lacks the side effects of increased sedation and respiratory depression, and may cause less nausea and vomiting which often contribute to delayed discharge (6). However, studies addressing ketorolac's efficacy in reducing moderate to severe postoperative pain after outpatient surgical procedures have been inconsistent (7-11). These differences in results may be partly explained by the confounding effects of differences in the operative procedures, type and severity of pain, and use of opioids.
Previous studies have found that ketorolac alone was not an effective intraoperative and postoperative analgesic for laparoscopic surgery (8,121. Previous pilot studies (12,13) have also revealed that the pain after laparoscopic tubal ligation (TL) may be greater than that after diagnostic laparoscopy (DL). Therefore, in the present study, patients undergoing outpatient laparoscopy were stratified into two groups: DL procedures and TL procedures. The purpose of this prospective stratified double-blind randomized study was to determine whether the addition of ketorolac to a standard fentanyl, propofol/nitrous oxide anesthetic would improve postoperative pain control and or reduce side effects in outpatients undergoing DL or TL.
Methods
This study was approved by our institutional review board and each patient gave written, informed consent before entering the study. One hundred twentysix adult female patients scheduled for either outpatient DL or TL procedures were enrolled. All patients had a physical status classification of ASA I or II and were 18-50 yr of age. Women with a prior history of allergy to NSAIDs, hiatal hernia, bleeding disorders, weight greater than 90 kg, a history of current opioid/narcotic usage, or current or prior substance abuse were excluded from this study. During the preoperative period, each patient was instructed in the use of a lo-cm visual analog pain scale (VAS) with a scale of 0 = no pain to 10 = severe pain, to assess the severity of postoperative pain. Patients in the DL sample usually underwent a laparoscopic procedure as a part of an infertility workup.
In the TL sample, all procedures were performed by the application of Falope@ ring bands (Cabot Medical Corp., Langhorne, PA) to the fallopian tubes. Patients were allocated to the following treatment groups by way of two separate random number schemes: 1) DL -Group I, fentanyl + saline (FS) (n = 40) and Group II, fentanyl + ketorolac (FK) (n = 40); 2) laparoscopic (TL) -Group I, fentanyl + saline (FS) (n = 23) and Group II, fentanyl + ketorolac (FK) (n = 23).
In the preoperative holding room, all patients received midazolam 1 or 2 mg intravenously (IV) as a premedicant.
The dosage of midazolam (1 or 2 mg) was based upon the anesthesiologist's discretion and depended upon the perceived need for anxiolysis. The patient was taken to the operating suite and standard anesthetic monitorsblood pressure, pulse oximetry, and electrocardiogramwere placed. Each patient received fentany12 pg/kg IV and lidocaine 40 mg IV (to reduce pain on injection of propofol) before the induction of anesthesia with propofol 2.5 mg/kg. Muscle relaxation and endotracheal intubation were facilitated with vecuronium 0.08 mg/kg IV. General endotracheal anesthesia was maintained via a variable infusion of propofol at 100-200 pg * kg-i * min-', and 70% nitrous oxide in oxygen. Ventilation was mechanically controlled to an ETco, of approximately 35 mm Hg. The patient's muscle relaxation was maintained with additional vecuronium, if needed, at 90% neuromuscular block. Neuromuscular block was determined by stimulation of the ulnar nerve with a peripheral nerve stimulator on a train-of-four mode. Approximately 30 min before the anticipated end of the surgical procedure, each patient received either 2 mL of placebo (saline) or ketorolac 60 mg IV from a blinded syringe, per a random list. The patient, the anesthesiologist, and the investigator were blinded to the treatment group. The propofol infusion was discontinued when the trocar was removed from the abdominal cavity, which is approximately 5 min before the last suture was placed. The muscle relaxant was reversed with neostigmine 2.5 mg and glycopyrrolate 0.6 mg IV when the last suture was placed and the N,O was discontinued when the bandage was placed. The patient then received 100% oxygen. The trachea was extubated when there was no demonstrable residual neuromuscular blocking effect by peripheral nerve stimulation and clinical signs. The time of extubation, the total maintenance dose of propofol, the time of discontinuation of nitrous oxide, and the time the patient responded to verbal commands were all documented.
Once the patient arrived in the postanesthesia care unit (PACU) and was awake, each patient was asked to assess her pain via a lo-cm VAS as she had been instructed preoperatively.
Patients with moderate to severe pain (VAS greater than 5) were treated with incremental doses of fentanyl25-50 p.g for pain relief by a PACU nurse who was blinded to the treatment groups. The PACU nurse could repeat fentanyl in the same doses (up to a maximum total of 200 pg), when the VAS pain score persisted above 5 and when 5 min had elapsed between the doses. A blinded investigator (SPK) monitored the patient's vital signs, VAS pain scores, and incidence of side effects every 30 min until discharge. Any nausea and/or vomiting in the PACU or in Phase II PACU was documented as postoperative nausea and/or vomiting (PONV). Any nausea which persisted more than 5 min and any vomiting, was treated with prochlorperazine 5 mg IV. Once the patients in both samples could tolerate oral intake, ibuprofen or acetaminophen with codeine was given for pain control. The times at which patients could tolerate oral intake, ambulate, void, and were ready for discharge were documented. The blinded observer continued to document any postoperative side effects until the time of discharge. The same blinded observer contacted each patient by telephone 24 h after discharge to follow her home postoperative course and review any possible anesthetic or surgical side effects.
A power analysis was performed (14). An expected difference of 50% of the percentage of women requiring fentanyl administration in the PACU yielded a total sample size of 80. The sample size thus consisted of 40 women per treatment arm; for each of the two segments of this study, i.e., TL sample and DL sample, for a total of 160 participants.
Sample size calculations for each segment (n = 80) determined that sufficient patients were studied to predict a difference with a power of 90% (p error = 10% and CY error = 5%). Soon after the initiation of this study the authors' clinical impression was that the TL sample was experiencing intense pain irrespective of the treatment group. When 46 patients (23 patients in each sample) were completed, the data were analyzed in consultation with a biostatistician. It became clear that the TL sample had far more pain than the DL sample despite the administration of ketorolac, and that there was no opioidsparing effect in this population. The TL limb of the study was discontinued at that time because it was unlikely to reach statistical significance and it seemed inappropriate to continue; thus this explains the unequal sample sizes in the DL sample versus the TL sample. Results were tabulated and statistical analysis was completed using the 2 (contingency table) and Student's t-tests. Multiple comparisons were corrected using the Bonferroni adjustment which was made separately for each segment of analyses and for each variable, e.g., DL, FS versus FK, or TL, FS versus FK separately. A P value less than 0.05 was considered to be statistically significant. All data are expressed as mean 2 SD.
Results
The demographic data revealed that the two treatment groups for each segment of the study and the two patient samples were similar. Table 1 shows that the age, height, and weight were comparable among the two patient samples and the treatment groups. Table 1 also describes intraoperative medications and anesthesia. The average (mean 2 SD) duration of surgery (52 ? 31 min), anesthesia (88 f 32 min), mean propofol maintenance dose (638 + 294 mg), and times to administration of ketorolac (21 5 19 min) were comparable between treatment groups in the DL sample.
In the laparoscopic TL sample the average (mean + SD) duration of surgery (31 -C 16 min), anesthesia (65 ? 16 min), mean propofol maintenance dose (531 5 204 mg), and times to administration of ketorolac (30 + 17 min) were also similar between treatment groups.
However, there were significant differences for comparable treatment groups between the DL and TL samples. Immediate emergence from anesthesia was determined from discontinuation of N,O. This category included time to eye opening, first response to verbal command, and the time at which the patient was determined to be alert and oriented to time, place, and person which were similar in the sample. The TL sample treated with ketorolac were tracheally extubated and considered to be alert and oriented statistically sooner (P < 0.05). Table 2 describes the notable differences in the severity of pain and treatment between the two patient samples and between the respective treatment groups. The initial VAS pain scores were significantly lower (6.3 ? 1.9 vs 4.6 + 2.9) in women treated with ketorolac after DL (P < 0.005). As also shown in Table 2 , the significantly improved VAS pain scores also continued 30 min after arrival in the PACU. Ninety-two percent of the DL patients in the saline group required treatment for their postoperative pain as opposed to 75% in the ketorolac 60 mg group (P < 0.05). Seventy percent of the DL patients in the saline group required IV fentanyl for analgesia as opposed to 37.5% in the ketorolac 60 mg group (P < 0.005). However, when a patient received ketorolac during DL and then required fentanyl for postoperative analgesia, the dose required (mean + SD) was not different than the dose necessary for pain management in the placebo treatment group (67 + 29 PLg vs 67 2 35 pg>.
The patients in the TL sample reported pain scores of at least 7 in both treatment groups ( Table 2 ). The initial VAS pain scores in the TL sample were significantly higher than in the DL sample (7.3 + 2.2 vs 4.6 t 2.2) for the patients who received ketorolac (P < 0.05). The percentage of TL patients who required fentanyl in the PACU for management of postoperative pain was significantly higher than in the DL sample for both the treatment and nontreatment groups (82.6% vs 37.5% for FK and 95.6% vs 70% for FS; P < 0.05). More than 80% of the TL patients required fentanyl for postoperative analgesia, but the mean dose was not significantly different among the treatment groups. In the nonketorolac group, the amount of fentanyl required in the TL sample (92 + 57 pg) was greater than in the DL sample (67 + 29 pg, P = 0.05).
The results concerning any nausea and/or vomiting in the PACU (Phase I and Phase II) are also presented in Table 2 as one entity. There were no differences in the incidence of PONV or therapeutic intervention for PONV within the respective treatment groups (FS vs FK) (Table 2) . However, the percentage of TL patients who experienced PONV was significantly higher in the TL sample when compared to the DL sample (52.2% for FS and 30.4% for FK versus 25% for FS and 10% for FK; P < 0.05). When treatment was required for PONV in the PACU, the percentage of patients in the TL sample requiring prochlorperazine was significantly higher than the corresponding DL sample (39.1% for FS and 26.1% for FK vs 12.5% for FS and 2.5% for FK; P < 0.05). Table 2 also shows the time required for the patient to meet the milestones for home readiness and discharge. Less time was required for the patient to achieve the milestones in the FK group in the DL sample. In particular, in the DL sample the ketorolac group was able to ambulate and void and be discharged home significantly earlier than their nonketorolac counterparts (P < 0.05) ( Table 2) . However, there were no differences in the TL sample for home readiness or discharge. Despite overall longer surgical procedures for the DL sample (Table 11 , they spent less time in the PACU and were discharged home significantly sooner, than the comparable patients in TL sample (P < 0.05).
Discussion
The results of this study suggest that IV ketorolac (60 mg) given 30 minutes before the expected end of the operation, but after fentanyl (2 pg/kg) given at the time of induction of anesthesia, has a postoperative opioid-sparing effect which allowed for earlier discharge in women undergoing DL. The beneficial effects of ketorolac (60 mg) were not found in women undergoing TL.
The efficacy of ketorolac in relieving severe postoperative pain in the outpatient population is controversial. While some authors have reported that ketorolac has a opioid-sparing effect, i.e., a diminution in both parental and oral analgesic requirements in women undergoing outpatient laparoscopy (7, 11, 15) , others have concluded that ketorolac did not exhibit a postoperative opioid-sparing effect (10, 12, 16) . Additional studies have concluded that oral NSAIDs like piroxicam 40 mg or naproxen sodium 550 mg given prior to outpatient gynecological laparoscopic procedures were effective in preventing postoperative pain (15,171. However, Edwards et al. (18) found diclofenac 75 mg intramuscularly was not effective in preventing pain after laparoscopic sterilization. Shapiro and Duffy (9) also found that the prophylactic administration of 30 mg of ketorolac immediately after induction of anesthesia in women undergoing laparoscopic sterilization with Hulka clips was not effective, since there was no difference in opioid requirements or pain scores. Bellamy et al. (19) reported slightly less nausea in patients receiving ketorolac when compared to placebo, as well as a reduction in the time to discharge from the PACU. The dose and the time when the NSAID and the opioids were given may have influenced the results. It is well documented that ketorolac is beneficial for pain after various types of orthopedic surgery (20, 21) . However, studies of ketorolac for pain control after various gynecologic surgeries yielded equivocal results. These studies have often evaluated data pooled from a variety of procedures, i.e., dilation and curettage, laparoscopic TL, DL and laser procedures (6) (7) (8) (10) (11) (12) 15, 19) .
Ketorolac may be a valuable alternative or adjunct to an opioid in alleviating certain types of postoperative pain but not others. The major drawback of some of these earlier papers is that they did not compare similar patient populations (6) (7) (8) (10) (11) (12) 15, 19) .
Shapiro and Duffy (9) limited their study population to patients undergoing laparoscopic TL with Hulka clips only and used a lower dose of ketorolac (30 mg) but were unable to show any benefit. We have used a higher dose of ketorolac, 60 mg, and still were unable to show a difference. Despite the contention by Comfort et al. (17) that naproxen sodium is useful in the TL population, their data are confounded by the two types of surgical techniques, i.e., coagulation versus the Felsche clips. The TL sample in the present paper is limited to Falope@ rings only. However, the DL sample also includes lysis of adhesions. The results presented here reflect the first study to limit the patient population to two separate and distinct samples of women undergoing outpatient laparoscopy, i.e., DL and laparoscopic TL. Preliminary data from our institution suggested that fentanyl 1 pg/kg was ineffective in controlling postoperative pain after laparoscopic surgery (12). Consequently, a fentanyl dose of 2 pg/kg was selected, which is a common dose for use in short outpatient procedures.
This dose of fentanyl provided good intraoperative analgesia; however, it did not provide extended pain relief in the postoperative period either in the DL or TL sample. A 60-mg dose of ketorolac was chosen since it is considered to be roughly equipotent to morphine 6-12 mg (3-5) . The use of a 60-mg dose may be criticized by some, since the manufacturer's new current recommendation is to start with a 30-mg dose. We justified the 60-mg ketorolac dose because we were planning to use only one dose of ketorolac for the day. Moreover, our study population consisted of healthy young patients with no organ dysfunction (e.g., chronic kidney disease).
A balanced analgesic technique, i.e., the combination of ketorolac 60 mg, an inhibitor of prostaglandin synthesis, 30 minutes before the end of the procedure, in conjunction with a moderate dose of intraoperative fentanyl at induction, resulted in significant opioid sparing during the postoperative period after DL. The use of the 60-mg dose of ketorolac also allowed both the DL and TL patients to be discharged home earlier than the fentanyl-only group. Another study specifically looking at cost would be in order to better evaluate whether the cost difference is clinically significant.
The present work demonstrates significant differences in pain scores between patients undergoing DL and laparoscopic TL, which further supports the hypothesis that pain intensity is a determining factor in outcome. Davis and Millar (13) came to the same conclusion earlier. Our study found that the addition of IV ketorolac (60 mg) to fentanyl intraoperatively, in patients presenting for laparoscopic TL, did not provide any additional analgesia. The reason for the apparent lack of opioid sparing of ketorolac in the TL population is unclear. We speculate that the application of rings to the fallopian tubes may cause ischemia of the fallopian tubes that may be associated with spasm of the tubes or peritoneal irritation and cause severe postoperative pain. The most likely explanation of failure of the ketorolac/fentanyl combination to show any difference from fentanyl alone may also be due to the so called "background noise" effect. The severe postoperative pain in the TL sample may have masked any real difference between the two groups. Elucidation of the etiology of the pain mechanism in the TL patient population may help in the design of a better pain control regimen to meet their postoperative analgesic needs. A different regimen, possibly involving intraoperative nerve blocks, more potent analgesics, and preemptive use of analgesics might provide better postoperative pain control. Ketorolac or saline was administered approximately 30 minutes before the end of the operation, since the length of operations are always unpredictable.
Ketorolac was not administered during the preoperative period because this practice would produce different blood levels of ketorolac upon arrival in the PACU. This variable was eliminated by giving ketorolac or saline 30 minutes from the anticipated end of the operation. However, this practice might have hampered the full effectiveness of ketorolac. Administering ketorolac preemptively (before surgical stimulation) may be more effective in providing meaningful postoperative analgesia. Oral naproxen when given preemptively as a premeditation was more effective than placebo in controlling postoperative pain after laparoscopic TL (17). In conclusion, in women undergoing DL, intraoperative ketorolac 60 mg IV in combination with fentanyl 2 pg/kg IV was shown to have a significant opioidsparing effect during the postoperative period compared to those who received the same dose of fentanyl alone. The DL patients receiving this combination 1996;82:732-7 KETOROLAC, POSTOPERATNE PAIN, AND LAPAROSCOPY were discharged home earlier and had significantly less nausea and vomiting compared to the group that received fentanyl alone. However, in women undergoing laparoscopic TL procedure, the impact of adding ketorolac 60 mg with fentanyl 2 pg/kg was not evident, and there were no significant differences in postoperative pain scores, analgesic requirements, the incidence of postoperative side effects, or discharge time. The reason for the different response in the TL sample is unclear. It may be due to the greater severity of pain in the TL sample which has masked any potential difference ("background noise" effect). This also suggests that laparoscopic TL and DL procedures should be considered as separate entities when designing analgesic regimens. 
